跳至主要内容
临床试验/ACTRN12617001505392
ACTRN12617001505392已完成4 期

Do clinical doses of neostigmine induce muscle weakness, when administered to awake volunteers, in the absence of exposure to any non-depolarising neuromuscular blocking agents and if so does this have features of depolarising or non-depolarising blockade?

Australian Society of Anaesthetists0 个研究点目标入组 21 人开始时间: 2017年10月25日最近更新:

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
21

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 60 Years(—)
性别
All

入选标准

  • We recruited healthy volunteers with American Society of Anesthesiologists (ASA) class I physical status to participate in the study.

排除标准

  • Pregnancy, history of neuromuscular or respiratory disease, or any condition that may interfere from the conduct of the study, such as allergy to the study medications or adhesive gel electrodes, currently taking any medication that may affect neuromuscular or respiratory function, or interfere with the study medications. ASA status equal to or greater than 2,

研究者

发起方
Australian Society of Anaesthetists

相似试验

Administration of clinical doses of neostigmine,... | 临床试验